Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging

Willecke‑Hochmuth,Regina; Pachmann,Katharina; Drevs,Joachim

doi:10.3892/ol.2016.4878

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging

Authors:
- Regina Willecke‑Hochmuth
- Katharina Pachmann
- Joachim Drevs
View Affiliations

Affiliations: Transfusion Medical Centre Bayreuth, D‑95448 Bayreuth, Germany, UNIFONTIS Clinic, D‑72076 Tübingen, Germany
Published online on: July 18, 2016 https://doi.org/10.3892/ol.2016.4878
Pages: 1711-1716
Copyright: © Willecke‑Hochmuth et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection and characterisation of tumour-derived circulating epithelial tumor cells (CETCs) or circulating tumor cells (CTCs) have been a main focus of basic oncological research over previous years. Numerous studies in the past decade have shown that CTCs are a promising tool for the estimation of the risk for metastatic relapse. The present observational study describes treatment results using tumour imaging and the quantification of CTCs. A group of 14 patients with advanced carcinomas was followed during their anticancer treatments. CTC numbers were serially detected and treatment success was estimated by positron emission tomography‑computed tomography. A connection was found between tumour remission and a decreasing CTC count in 83%, a connection between stable disease and stable CTC numbers in 78% and a connection between progressive disease (PD) and an increase in CTC count in 50% of cases. In the patients with PD, an incomplete response was observed affecting the CTCs, but not the solid region of the tumour. As a result of this study, it may be concluded that patients with solid tumours benefit from serial quantification of CTCs in addition to imaging, as this combination of techniques provides a more sensitive result than imaging alone.

View Figures

View References

1	Thun MJ, Henley SJ and Patrono C: Nonsteroidal Anti-inflammatory drugs as anticancer agents: Machanistic, pharmarcologic and clinical issues. J Natl Cancer Inst. 94:252–266. 2002. View Article : Google Scholar : PubMed/NCBI
2	Claudius AK, Kankipati CS, Kilari RS, Hassan S, Guest K, Russell ST, Perry CJ, Stark LA and Nicholl ID: Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo. Ocol Rep. 32:1670–1680. 2014.
3	Ulrich CM, Bigler J and Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer. 6:130–140. 2006. View Article : Google Scholar : PubMed/NCBI
4	Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M and Pachmann K: NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: Particular relevance to triple negative subgroup. Breast Cancer Res Treat. 134:881–888. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kreutz W: Diflunisal for the treatment of cancer. German Patent WO/2005/016354. Filed August 18, 2004. Issued February 24. 2005.
6	Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE and Trask DK: Relative non-steriodal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog. 46:857–864. 2007. View Article : Google Scholar : PubMed/NCBI
7	Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wang RA, Lu YY and Fan DM: Reasons for cancer metastasis: A holistic perspective. Mol Clin Oncol. 3:1199–1202. 2014.
9	Plaks V, Koopman CD and Werb Z: Circulating Tumor Cells. Science. 341:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
10	Gaorav GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
11	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2002. View Article : Google Scholar
12	Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW and Hayes DF: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 12:6403–6409. 2006. View Article : Google Scholar : PubMed/NCBI
13	Pachmann K, Camara O, Kavallaria A, Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, et al: Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 26:1208–1215. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pachmann K, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R and Pachmann U: An increase in cell number at completion of therapy may develop as an indicator of early relapse: Quantification of CETC for monitoring of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol. 134:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
15	Pachmann K, Camara O, Kavallis A, Schneider U, Schünemann S and Höffken K: Quantification of the response of circulating epithelial cells to neoadjuvant treatment for breast cancer: A new tool for treatment monitoring. Breast Cancer Res. 7:R975–R979. 2005. View Article : Google Scholar : PubMed/NCBI
16	Reichle A and Vogt T: Systems Biology: A Therapeutic Target for Tumor Therapy. Cancer Microenviron. 1:159–170. 2008. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
18	Rüdiger N, Stein EL, Schill E, Spitz G, Rabenstein C, Stauch M, Rengsberger M, Runnebaum IB, Pachmann U and Pachmann K: Chemosensitivity testing of circulating epithelial tumor cells (cetc) in vitro: Correlation to in vivo sensitivity and clinical outcome. J Cancer Ther. 4:597–605. 2013. View Article : Google Scholar
19	Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jörke C, Rabenstein C, Untch M and Pachmann K: The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol. 18:1484–1492. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hekimian K, Meisezahl S, Trompelt K, Rabenstein C and Pachmann K: Epithelial cell dissemination and readhesion: Analysis of factors contributing to metastasis formation in breast cancer. ISRN Oncol. 2012:6018102012.PubMed/NCBI
21	Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar : PubMed/NCBI
22	Munson JM and Shieh AC: Interstitial fluid flow in cancer: Implications for disease progression and treatment. Cancer Manag Res. 6:317–328. 2014. View Article : Google Scholar : PubMed/NCBI
23	Yu JQ and Cristofanilli M: Circulating tumor cells and PET. J Nucl Med. 52:1501–1504. 2011. View Article : Google Scholar : PubMed/NCBI